RegenXBio (RGNX) Gets a Buy Rating from Chardan Capital

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on RegenXBio (RGNX) today and set a price target of $150. The company’s shares closed yesterday at $51.43.

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 19.4% and a 52.2% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Logicbio Therapeutics Inc, Voyager Therapeutics Inc, and Axovant Gene Therapies.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for RegenXBio with a $102.50 average price target, representing a 99.3% upside. In a report issued on June 13, Raymond James also resumed coverage with a Buy rating on the stock with a $60 price target.

See today’s analyst top recommended stocks >>

Based on RegenXBio’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $32.23 million. In comparison, last year the company had a net profit of $104 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.